Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study

dc.contributor.author	Martens, Alexander
dc.contributor.author	Wistuba-Hamprecht, Kilian
dc.contributor.author	Zelba, Henning
dc.contributor.author	Lipp, Hans-Peter
dc.contributor.author	Klumpp, Bernhard
dc.contributor.author	Soffel, Daniel
dc.contributor.author	Garbe, Claus
dc.contributor.author	Weide, Benjamin Matthias
dc.contributor.author	Eigentler, Thomas Kurt
dc.date.accessioned	2017-05-04T12:42:51Z
dc.date.available	2017-05-04T12:42:51Z
dc.date.issued	2016-12-22
dc.identifier.issn	1432-0851
dc.identifier.issn	0340-7004
dc.identifier.uri	http://hdl.handle.net/10900/76098
dc.language.iso	en	de_DE
dc.publisher	Cancer Immunology Immunotherapy	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s00262-016-1944-0	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	500	de_DE
dc.subject.ddc	610	de_DE
dc.title	Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study	de_DE
dc.type	Article	de_DE
utue.personen.roh	Weide, Benjamin
utue.personen.roh	Martens, Alexander
utue.personen.roh	Wistuba-Hamprecht, Kilian
dcterms.isPartOf.ZSTitelID	Cancer Immunology Immunotherapy	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE